Identifying Children With Leukemia Predisposition Syndromes

Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

This video reviews classic syndromes associated with increased leukemia susceptibility and highlights pediatric patients who may be at increased risk for an inherited leukemia predisposition and should receive additional work-up.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Sharon A. Savage, MD, of the National Institutes of Health in Bethesda, Maryland, reviews classic syndromes associated with increased leukemia susceptibility and highlights pediatric patients who may be at increased risk for an inherited leukemia predisposition and should receive additional work-up.

      Savage gave a presentation on this topic during an education session at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.

      Recent Videos
      More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
      Bexmarilimab Shows Survival Efficacy in Relapsed/Refractory MDS
      The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
      Creating an Accommodating Pediatric Cancer Care Experience
      Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
      Spreading Greater CAR T-Cell Therapy Education in the Community Setting
      Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
      Avoiding CAR T-Cell Collection Problems Following Bridging Therapies
      Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
      Academic/Community Collaboration May Help Facilitate CAR T Therapy Access
      A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
      Hybrid Model of CAR T-Cell Therapy May Help Manage Treatment-Related Infections
      A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
      Secondary Malignancies Risk Still in Question Following CAR T-cell Therapy for Lymphoma
      A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
      Study Aims to Address CAR T Accessibility Among Disadvantaged Groups
      Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
      Addressing Challenges in TP53-Mutant Acute Myeloid Leukemia
      Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
      Menin Inhibitor Developments Move Acute Myeloid Leukemia Landscape Forward
      Related Content
      BGB-16673 antitumor activity occurred particularly among patients with BTK-resistant mutations and those refractory to prior cBTK and ncBTK inhibition.

      BGB-16673 Shows Tolerability, Activity in Waldenström Macroglobulinemia

      Roman Fabbricatore
      June 19th 2025
      Article

      BGB-16673 antitumor activity occurred particularly among patients with BTK-resistant mutations and those refractory to prior cBTK and ncBTK inhibition.

      An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

      CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

      Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
      June 9th 2025
      Podcast

      An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

      Preparing for Oncology Board Certification, Career Transitions, and Combating Burnout

      Preparing for Oncology Board Certification, Career Transitions, and Combating Burnout

      ONCOLOGY Staff
      June 18th 2025
      Article

      Read about various aspects of career trajectories in oncology from the perspective of established clinicians, new attendings, and those waiting to sit for their medical board exams.

      Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

      Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

      Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
      May 5th 2025
      Podcast

      Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

      Data from APPULSE-PNH may support oral iptacopan as a potentially practice-changing option in patients with paroxysmal nocturnal hemoglobinuria.

      Iptacopan Yields Meaningful Hemoglobin Improvements in Pretreated PNH Group

      Russ Conroy
      June 13th 2025
      Article

      Data from APPULSE-PNH may support oral iptacopan as a potentially practice-changing option in patients with paroxysmal nocturnal hemoglobinuria.

      Treatment with cyclosporin/cyclophosphamide following allogeneic stem cell transplant had improved efficacy vs cyclosporin/methotrexate in patients with high-risk hematologic cancers.

      Cyclosporin/Cyclophosphamide Is a Potential New SOC in GVHD Management

      Ariana Pelosci
      June 13th 2025
      Article

      Treatment with cyclosporin/cyclophosphamide following allogeneic stem cell transplant had improved efficacy vs cyclosporin/methotrexate in patients with high-risk hematologic cancers.